The TMVR procedure with SAPIEN M3 involves dock and valve delivery via a percutaneous femoral vein guide sheath.

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first ...

IRVINE, CA. -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark in Europe for valve-in-valve ...

IRVINE, Calif., Oct. 15, 2015 -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making ...

First-of-its-kind Edwards SAPIEN M3 transcatheter mitral valve system secures FDA approval for transseptal mitral ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.

VANCOUVER, Wash. (AP) — Glenn Baker was just 32 years old when he underwent a relatively new surgical procedure in 1966 to replace a heart valve. This week, the 82-year-old and his family will ...